PPLPHARMA Q1 FY27 Guidance vs Delivery (PPLPHARMA Management Mirror)

Revenue Growth Rebounds to 17% in Jun'26 Qtr; Full-Year FY27 Guidance Reaffirmed

In the Sep'25 Qtr, management moderated its full-year FY26 revenue guidance to remain flat due to slower-than-expected growth in CDMO and Complex Hospital Generics (CHG). In the Dec'25 Qtr, management reaffirmed the FY26 guidance while noting it remained a stretch. For the Dec'25 Qtr, revenues were reported at INR 2,140 crores, representing a YoY decline of 3% to 4%. Moving to the Jun'26 Qtr (Q1 FY27), the company reported strong revenue growth of 17% YoY to INR 2,270 crores, driven by mid to high-teen growth across CDMO, CHG, and Consumer Healthcare. Management reaffirmed its full-year guidance for FY27 across all business segments, though noted that delivery patterns can fluctuate QoQ and any potential revisions will be evaluated after the Sep'26 Qtr results.